Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Accounts Payables (2016 - 2025)

Tg Therapeutics (TGTX) has 10 years of Accounts Payables data on record, last reported at $107.5 million in Q4 2025.

  • For Q4 2025, Accounts Payables rose 84.42% year-over-year to $107.5 million; the TTM value through Dec 2025 reached $107.5 million, up 84.42%, while the annual FY2025 figure was $107.5 million, 84.42% up from the prior year.
  • Accounts Payables reached $107.5 million in Q4 2025 per TGTX's latest filing, down from $112.3 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $134.0 million in Q2 2025 and bottomed at $29.7 million in Q3 2022.
  • Average Accounts Payables over 5 years is $68.2 million, with a median of $54.2 million recorded in 2021.
  • Peak YoY movement for Accounts Payables: tumbled 33.5% in 2022, then skyrocketed 155.17% in 2024.
  • A 5-year view of Accounts Payables shows it stood at $51.3 million in 2021, then decreased by 18.08% to $42.0 million in 2022, then decreased by 8.44% to $38.5 million in 2023, then surged by 51.53% to $58.3 million in 2024, then surged by 84.42% to $107.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accounts Payables were $107.5 million in Q4 2025, $112.3 million in Q3 2025, and $134.0 million in Q2 2025.